Clinical Trial !!!

TEST TEST ERC is recruiting patients for a phase II clinical trial.


A New Treatment For Brain Cancer

ERC is developing a unique advanced cancer cell based immunotherapy invented by Pr. Apostolos Stathopoulos for the treatment of patients suffering from brain cancers. This therapeutic vaccine known as ERC1671 (Gliovac™) particularly targets high grade gliomas.  





Scientific Innovation

ERC is developing ERC1671 (Gliovac™) cell and cell lysate vaccine to target high grade gliomas including glioblastoma multiforme and gliosarcoma. Currently, FDA approved a phase II clinical study of ERC1671 cell and lysate vaccine is underway.



International Support

ERC has established a global network of partnerships with internationally well-known academic and research institutions.